Raymond James Upgrades Alnylam Pharmaceuticals to Strong Buy, Maintains Price Target to $420

Benzinga · 1d ago
Raymond James analyst Martin Auster upgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) from Outperform to Strong Buy and maintains the price target from $420 to $420.